NCT06519591View on ClinicalTrials.gov

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Gastric Cancer Stage IVPeritoneal Metastases
Interventions
DRUG

Cadonilimab, LM-302, S-1, paclitaxel

Cadonilimab 10mg/kg, LM-302 2.0mg/kg intravenous (IV) infusion on day 1, paclitaxel 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER